Greenwich LifeSciences Inc
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
AS OF DECEMBER 31, 2023 AND 2022
| 2023 | 2022 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash | $6,989,424 | $13,468,026 |
| Acquired patents, net | 5,391 | 9,003 |
| Total assets | $6,994,815 | $13,477,029 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities | ||
| Accounts payable & accrued interest | $256,317 | $220,845 |
| Unreimbursed expenses | 38,089 | 42,060 |
| Total current liabilities | 294,406 | 262,905 |
| Total liabilities | 294,406 | 262,905 |
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 12,848,165 shares issued and outstanding as of December 31, 2023 and 2022 | 12,848 | 12,848 |
| Additional paid-in capital | 57,052,130 | 54,674,042 |
| Accumulated deficit | (50,364,569) | (41,472,766) |
| Total stockholders’ equity | 6,700,409 | 13,214,124 |
| Total liabilities and stockholders’ equity | $6,994,815 | $13,477,029 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.